COVID-19 and (hydroxy)chloroquine-azithromycin combination: Should we take the risk for our patients?
作者： Hervé Javelot , Wissam El‐Hage , Guillaume Meyer , Guillaume Becker , Bruno Michel
DOI: 10.1111/BCP.14335
关键词: 2019-20 coronavirus outbreak 、 QT interval 、 Azithromycin 、 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 、 Virology 、 Hydroxychloroquine 、 Pandemic 、 Chloroquine 、 Coronavirus disease 2019 (COVID-19) 、 Medicine
摘要:
sci-hub.se 参考文章(5)
Jules C Hancox, Mehrul Hasnain, W Victor R Vieweg, Ericka L Breden Crouse, Adrian Baranchuk, None, Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: A narrative review based on the study of case reports. Therapeutic Advances in Infectious Disease. ,vol. 1, pp. 155- 165 ,(2013) , 10.1177/2049936113501816
Eline Vandael, Bert Vandenberk, Joris Vandenberghe, Rik Willems, Veerle Foulon, Risk factors for QTc-prolongation: systematic review of the evidence International Journal of Clinical Pharmacy. ,vol. 39, pp. 16- 25 ,(2017) , 10.1007/S11096-016-0414-2
Raymond L. Woosley, Kristin Black, C. William Heise, Klaus Romero, CredibleMeds.org: What does it offer? Trends in Cardiovascular Medicine. ,vol. 28, pp. 94- 99 ,(2018) , 10.1016/J.TCM.2017.07.010
Christian A. Devaux, Jean-Marc Rolain, Philippe Colson, Didier Raoult, New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? International Journal of Antimicrobial Agents. ,vol. 55, pp. 105938- 105938 ,(2020) , 10.1016/J.IJANTIMICAG.2020.105938
Hao Yao, Jian-Hua Chen, Yi-Feng Xu, Patients with mental health disorders in the COVID-19 epidemic. The Lancet Psychiatry. ,vol. 7, ,(2020) , 10.1016/S2215-0366(20)30090-0